HWHG: Dapoxetine Hydrochloride Tablets have obtained the drug registration certificate
I'm PortAI, I can summarize articles.
HWHG's subsidiary Jiulong HWHG recently obtained the drug registration certificate for Dapoxetine Hydrochloride Tablets approved by the National Medical Products Administration. This drug is used to treat male premature ejaculation. Jiulong HWHG submitted the marketing authorization application in July 2024, with research and development investment of approximately 10 million yuan, and production entrusted to Chongqing Boteng Pharmaceutical Co., Ltd. The national sales are expected to be around 1.1 billion yuan in 2024, with major competitors including Shandong Huabokai Sheng Biotechnology Co., Ltd. and others
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments